Kyowa Kirin Co., Ltd.
$14.43+0.00%(+$0.00)
TickerSpark Score
78/100
90
Valuation
90
Profitability
60
Growth
100
Health
50
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KYKOF research report →
52-Week Range36% of range
Low $12.42
Current $14.43
High $18.00
Companywww.kyowakirin.com
Kyowa Kirin Co. , Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide.
- CEO
- Abdul Hafeez Mullick
- IPO
- 2012
- Employees
- 5,669
- HQ
- Tokyo, JP
Price Chart
-5.29% · this period
Valuation
- Market Cap
- $7.55B
- P/E
- 17.26
- P/S
- 2.46
- P/B
- 1.41
- EV/EBITDA
- 7.49
- Div Yield
- 2.58%
Profitability
- Gross Margin
- 73.30%
- Op Margin
- 21.54%
- Net Margin
- 14.28%
- ROE
- 8.39%
- ROIC
- 9.32%
Growth & Income
- Revenue
- $497.26B · 0.34%
- Net Income
- $67.10B · 12.07%
- EPS
- $128.18 · 13.37%
- Op Income
- $102.36B
- FCF YoY
- 257.70%
Performance & Tape
- 52W High
- $18.00
- 52W Low
- $12.42
- 50D MA
- $13.81
- 200D MA
- $15.60
- Beta
- 0.10
- Avg Volume
- 666
Get TickerSpark's AI analysis on KYKOF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our KYKOF Coverage
We haven't published any research on KYKOF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KYKOF Report →